Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated July 13, 2023, titled "FDA issues complete response letter for PDP-716 NDA due to inspection findings at third-party API manufacturing facility".
Press Release Jul 13 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Sun Pharma Advanced Research Co. Ltd. on 6ix
Earlier from Sun Pharma Advanced Research
- Press Release Nov 18 2022
- SEZABY™ (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures
- Press Release Nov 09 2022
- Outcome of committee meeting
- Press Release Sep 29 2022
Later from Sun Pharma Advanced Research
- AGM Speech 2022-23
- Press Release Oct 19 2023
- Sun Pharma Advanced Research Co. Ltd. Press Release Oct 30 2023
- Sun Pharma Advanced Research Co. Ltd. Press Release Nov 02 2023
- Press Release Jan 04 2024
Follow Sun Pharma Advanced Research into a list and get an email when it puts out news.
Follow Sun Pharma Advanced Research